Curative Biotechnology Inc Intellectual Property Contracts & Agreements
20 Contracts & Agreements
- License Agreements (20 contracts)
- Amendment Number 1 to Patent License Agreement dated March 19, 2024 between National Institute of Health and Curative Biotechnology, Inc. (f/k/a Connectyx Technologies Holdings... (Filed With SEC on May 6, 2024)
- Amendment Number 2 to Patent License Agreement -Exclusive Evaluation Option License dated November 17, 2023 between National Institute of Health and Curative Biotechnology, Inc.... (Filed With SEC on May 6, 2024)
- Amendment Number 1 to Patent License Agreement -Exclusive Evaluation Option License dated February 23, 2023 between National Institute of Health and Curative Biotechnology, Inc.... (Filed With SEC on May 6, 2024)
- First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc (Filed With SEC on November 7, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc (Filed With SEC on November 7, 2022)
- License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on November 7, 2022)
- Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on November 7, 2022)
- Patent License Agreement dated February 2, 2021 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group) (Filed With SEC on November 7, 2022)
- License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc (Filed With SEC on November 7, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc (Filed With SEC on September 9, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc (Filed With SEC on September 9, 2022)
- License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on September 9, 2022)
- Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on September 9, 2022)
- License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc (Filed With SEC on September 9, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc (Filed With SEC on April 15, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc (Filed With SEC on April 15, 2022)
- License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on April 15, 2022)
- Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on April 15, 2022)
- Patent License Agreement dated February 2, 2021 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group) (Filed With SEC on April 15, 2022)
- License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc (Filed With SEC on April 15, 2022)
